The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

dacarbazine     5- (dimethylaminohydrazinylidene) imidazole...

Synonyms: dacarbazina, DTCI, AC1NQXVV, SureCN5560, SureCN6372, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of dacarbazine


High impact information on dacarbazine


Chemical compound and disease context of dacarbazine


Biological context of dacarbazine


Anatomical context of dacarbazine


Associations of dacarbazine with other chemical compounds


Gene context of dacarbazine


Analytical, diagnostic and therapeutic context of dacarbazine


  1. Adjuvant dacarbazine in cutaneous melanoma. Runne, U., Pullmann, H., Féaux de Lacroix, W. N. Engl. J. Med. (1983) [Pubmed]
  2. Case report: development of Hodgkin's disease in patient receiving long-term administration of dacarbazine and interleukin-2 for metastatic melanoma. Flaherty, L.E., Schwert, R., Redman, B.G. J. Natl. Cancer Inst. (1990) [Pubmed]
  3. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. Zalupski, M., Metch, B., Balcerzak, S., Fletcher, W.S., Chapman, R., Bonnet, J.D., Weiss, G.R., Ryan, J., Benjamin, R.S., Baker, L.H. J. Natl. Cancer Inst. (1991) [Pubmed]
  4. Successful treatment of metastatic glucagonoma with dacarbazine. Kurose, T., Seino, Y., Ishida, H., Fujita, J., Taminato, T., Matsukura, M., Imura, H. Lancet (1984) [Pubmed]
  5. Malignant glucagonoma syndrome: response to chemotherapy. Marynick, S.P., Fagadau, W.R., Duncan, L.A. Ann. Intern. Med. (1980) [Pubmed]
  6. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. Cocconi, G., Bella, M., Calabresi, F., Tonato, M., Canaletti, R., Boni, C., Buzzi, F., Ceci, G., Corgna, E., Costa, P. N. Engl. J. Med. (1992) [Pubmed]
  7. Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial. Flaherty, L.E., Liu, P.Y., Fletcher, W.S., Goodwin, J.W., Balcerzak, S.P., Daniels, D., Stephens, R.L., Sondak, V.K. J. Natl. Cancer Inst. (1992) [Pubmed]
  8. Nude rat model for studying metastasis of human tumor cells to bone and bone marrow. Kjønniksen, I., Nesland, J.M., Pihl, A., Fodstad, O. J. Natl. Cancer Inst. (1990) [Pubmed]
  9. Secondary cytotoxic response in vitro against Moloney lymphoma cells antigenically altered by drug treatment in vivo. Santoni, A., Kinney, Y., Goldin, A. J. Natl. Cancer Inst. (1978) [Pubmed]
  10. High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. Luger, S.M., Kirkwood, J.M., Ernstoff, M.S., Vlock, D.R. J. Natl. Cancer Inst. (1990) [Pubmed]
  11. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group. Bramwell, V., Quirt, I., Warr, D., Verma, S., Young, V., Knowling, M., Eisenhauer, E. J. Natl. Cancer Inst. (1989) [Pubmed]
  12. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Santoro, A., Bonfante, V., Bonadonna, G. Ann. Intern. Med. (1982) [Pubmed]
  13. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Averbuch, S.D., Steakley, C.S., Young, R.C., Gelmann, E.P., Goldstein, D.S., Stull, R., Keiser, H.R. Ann. Intern. Med. (1988) [Pubmed]
  14. Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication. Marsh, J.C. Hepatology (1989) [Pubmed]
  15. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Jansen, B., Wacheck, V., Heere-Ress, E., Schlagbauer-Wadl, H., Hoeller, C., Lucas, T., Hoermann, M., Hollenstein, U., Wolff, K., Pehamberger, H. Lancet (2000) [Pubmed]
  16. Prevention of dacarbazine damage of human neoplastic cell DNA by aphidicolin. Lönn, U., Lohn, S. Cancer Res. (1987) [Pubmed]
  17. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Stevens, M.F., Hickman, J.A., Langdon, S.P., Chubb, D., Vickers, L., Stone, R., Baig, G., Goddard, C., Gibson, N.W., Slack, J.A. Cancer Res. (1987) [Pubmed]
  18. In vivo drug sensitivity assay of clonogenic human melanoma cells and correlation with treatment outcome. Kirkwood, J.M., Marsh, J.C. Cancer Res. (1983) [Pubmed]
  19. Methylation of cysteine in hemoglobin following exposure to methylating agents. Bailey, E., Connors, T.A., Farmer, P.B., Gorf, S.M., Rickard, J. Cancer Res. (1981) [Pubmed]
  20. In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas. Testorelli, C., Franco, P., Goldin, A., Nicolin, A. Cancer Res. (1978) [Pubmed]
  21. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. Lev, D.C., Onn, A., Melinkova, V.O., Miller, C., Stone, V., Ruiz, M., McGary, E.C., Ananthaswamy, H.N., Price, J.E., Bar-Eli, M. J. Clin. Oncol. (2004) [Pubmed]
  22. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. DeLeve, L.D. Hepatology (1996) [Pubmed]
  23. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Divito, K.A., Berger, A.J., Camp, R.L., Dolled-Filhart, M., Rimm, D.L., Kluger, H.M. Cancer Res. (2004) [Pubmed]
  24. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. Adkins, D.R., Salzman, D., Boldt, D., Kuhn, J., Irvin, R., Roodman, G.D., Lyons, R., Smith, L., Freytes, C.O., LeMaistre, C.F. J. Clin. Oncol. (1994) [Pubmed]
  25. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. Eton, O., Legha, S.S., Bedikian, A.Y., Lee, J.J., Buzaid, A.C., Hodges, C., Ring, S.E., Papadopoulos, N.E., Plager, C., East, M.J., Zhan, F., Benjamin, R.S. J. Clin. Oncol. (2002) [Pubmed]
  26. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. Desch, C.E., Lasala, M.R., Smith, T.J., Hillner, B.E. J. Clin. Oncol. (1992) [Pubmed]
  27. Modulation of cisplatin resistance in human malignant melanoma cells. McClay, E.F., Albright, K.D., Jones, J.A., Eastman, A., Christen, R., Howell, S.B. Cancer Res. (1992) [Pubmed]
  28. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. Prosnitz, L.R., Farber, L.R., Kapp, D.S., Scott, J., Bertino, J.R., Fischer, J.J., Cadman, E.C. J. Clin. Oncol. (1988) [Pubmed]
  29. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response. Isacson, R., Kedar, E., Barak, V., Gazit, Z., Yurim, O., Kalichman, I., Ben-Bassat, H., Biran, S., Schlesinger, M., Franks, C.R. Immunol. Lett. (1992) [Pubmed]
  30. Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest. Sato, K., Kitajima, Y., Kohya, N., Miyoshi, A., Koga, Y., Miyazaki, K. Int. J. Oncol. (2005) [Pubmed]
  31. Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy. Ma, S., Egyházi, S., Ringborg, U., Hansson, J. Oncol. Rep. (2002) [Pubmed]
  32. Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations. Sanada, M., Takagi, Y., Ito, R., Sekiguchi, M. DNA Repair (Amst.) (2004) [Pubmed]
  33. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. Dillman, R.O., Oldham, R.K., Barth, N.M., Birch, R., Arnold, J., West, W.H. J. Natl. Cancer Inst. (1990) [Pubmed]
  34. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. Weber, R.W., O'Day, S., Rose, M., Deck, R., Ames, P., Good, J., Meyer, J., Allen, R., Trautvetter, S., Timmerman, M., Cruickshank, S., Cook, M., Gonzalez, R., Spitler, L.E. J. Clin. Oncol. (2005) [Pubmed]
WikiGenes - Universities